Dexamethasone abrogates the antimicrobial and antibiofilm activities of different drugs against clinical isolates of Staphylococcus aureus and Pseudomonas aeruginosa

Rodrigues, Aquila; Gomes, André Luiz Marques; Marçal, Pedro Henrique Ferreira; Dias-Souza, Marcus Vinícius

doi:10.1016/j.jare.2016.12.001

Cited by 17 publications

(19 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TPP 92096; Trasadingen, Switzerland) were filled with 135 l of TSB 1% glucose, and 15 l of bacterial suspension, prepared as described earlier, was added into each well, and the plate was incubated for 24 h at 37°C. After two washing steps with 200 l of sterile PBS (pH 7.2), 10% CFCM or control (in PBS) was added, and the plate was incubated for an additional 24 h at 37°C (60). Safranin staining and measurement were then performed as described above.…”

Section: Methodsmentioning

confidence: 99%

“…After 24 h of incubation at 37°C and two washing steps with 200 l of sterile PBS (pH 7.2), 10% CFCM or control with or without increasing concentrations of oxacillin (0.25 to 256 g/ml) were added, and plates were incubated for 24 h at 37°C. After a single washing step with PBS, the viability of biofilm cells was revealed using resazurin 0.02% for 3 h. A blue color indicated dead cells, whereas pink indicated live cells (60).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Small Molecules Produced by Commensal Staphylococcus epidermidis Disrupt Formation of Biofilms by Staphylococcus aureus

Glatthardt

Campos

Chamon

et al. 2020

Appl Environ Microbiol

View full text Add to dashboard Cite

The microbiota influences host health through several mechanisms, including protecting it from pathogen colonization. Staphylococcus epidermidis is one of the most frequently found species in the skin microbiota, and its presence can limit the development of pathogens such as Staphylococcus aureus. S. aureus causes diverse types of infections ranging from skin abscesses to bloodstream infections. Given the increasing prevalence of S. aureus drug-resistant strains, it is imperative to search for new strategies for treatment and prevention. Thus, we investigated the activity of molecules produced by a commensal S. epidermidis isolate against S. aureus biofilms. We showed that molecules present in S. epidermidis cell-free conditioned media (CFCM) caused a significant reduction in biofilm formation in most S. aureus clinical isolates, including all 4 agr types and agr-defective strains, without any impact on growth. S. epidermidis molecules also disrupted established S. aureus biofilms and reduced the antibiotic concentration required to eliminate them. Preliminary characterization of the active compound showed that its activity is resistant to heat, protease inhibitors, trypsin, proteinase K, and sodium periodate treatments, suggesting that it is not proteinaceous. RNA sequencing revealed that S. epidermidis-secreted molecules modulate the expression of hundreds of S. aureus genes, some of which are associated with biofilm production. Biofilm formation is one of the main virulence factors of S. aureus and has been associated with chronic infections and antimicrobial resistance. Therefore, molecules that can counteract this virulence factor may be promising alternatives as novel therapeutic agents to control S. aureus infections. IMPORTANCE S. aureus is a leading agent of infections worldwide, and its main virulence characteristic is the ability to produce biofilms on surfaces such as medical devices. Biofilms are known to confer increased resistance to antimicrobials and to the host immune responses, requiring aggressive antibiotic treatment and removal of the infected surface. Here, we investigated a new source of antibiofilm compounds, the skin microbiome. Specifically, we found that a commensal strain of S. epidermidis produces molecules with antibiofilm activity, leading to a significant decrease of S. aureus biofilm formation and to a reduction of previously established biofilms. The molecules potentiated the activity of antibiotics and affected the expression of hundreds of S. aureus genes, including those associated with biofilm formation. Our research highlights the search for compounds that can aid us in the fight against S. aureus infections.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Small Molecules Produced by Commensal Staphylococcus epidermidis Disrupt Formation of Biofilms by Staphylococcus aureus

Glatthardt

Campos

Chamon

et al. 2020

Appl Environ Microbiol

View full text Add to dashboard Cite

show abstract

“…In the case of biofilm formation, a minimum biofilm eradication concentration (MBEC) is required for antibiotic action, which is usually 100–1000 times higher than the MIC [ 17 ], and it is not possible to achieve the desired local MBEC antimicrobial concentrations by systemic administration alone. Among the bacteria detected in our case series, the usual MBEC for methicillin-sensitive Staphylococcus aureus (MSSA) to gentamicin is reported as approximately 1,000 μ g/mL [ 18 ]. In the CLAP therapy, we could deliver 1,200 μ g/mL of gentamicin, which exceeded the MBEC for the MSSA, directly to the wound, which may have contributed to the prompt infection control.…”

Section: Discussionmentioning

confidence: 99%

Continuous Local Antibiotics Perfusion Therapy for Acute Deep Infections after Open Fractures

Takahara¹,

Maruo²,

Takayama³

et al. 2022

Case Reports in Orthopedics

View full text Add to dashboard Cite

Unresolved bone and soft tissue infections remain a great hindrance to fracture management worldwide, both economically and functionally for the patient. For this purpose, the benefits of local antibiotic administration besides systemic therapy have been elucidated. We present a retrospective descriptive analysis of six patients (4 males and 2 females) with acute deep infections after open fractures managed using the continuous local antibiotic perfusion (CLAP) therapy. After sufficient debridement, gentamicin solution concentrated at 1,200 μg/mL was continuously infused (2 mL/h) for 7–12 days by syringe pump through an inlet tube placed on the infected area. The antibiotics injected into the infected area were both collected and perfused by negative pressure using a negative-pressure wound therapy system. After an average of 9.5 days of CLAP therapy, symptoms of infection disappeared, and the bacterial culture was negative. There were no cases of recurrence during the follow-up period, and no complications, such as acute renal failure, ototoxicity, allergic or hypersensitivity reactions, and impaired fracture healing, were observed. All six cases were successfully managed with the CLAP therapy without any serious side effects. CLAP therapy may be a potential treatment option for acute deep infections after open fractures.

show abstract

“…2017; Rodrigues et al . 2017). It has been proven that biofilm‐embedded strains are up to 100–1000 times resistant to antimicrobial drugs than their planktonic cells (Macià et al .…”

Section: Discussionmentioning

confidence: 99%

Potent synergistic combination of rosuvastatin and levofloxacin against Staphylococcus aureus : in vitro and in vivo study

Abdelaziz

El-Barrawy

El-Nagar

2020

J. Appl. Microbiol.

View full text Add to dashboard Cite

Aims The present study aims to evaluate the capability of rosuvastatin to synergize with levofloxacin against Staphylococcus aureus. Methods and Results Rosuvastatin inhibited the growth of S. aureus with minimum inhibitory concentration of 16 μg ml−1. Additionally, it showed a bactericidal effect at 4x minimum inhibition concentration. Using a checkerboard method, a synergistic effect was recorded when rosuvastatin was combined with levofloxacin showing against S. aureus isolate 28 (S 28). Furthermore, this combination was also able to display a significant reduction in biofilm formation (92·8%) and suppress the production of coagulase and β‐haemolysin, and virulence factors of S. aureus isolate 28. An animal model for wound infection was used to assess the therapeutic effect of the test combination, in vivo. It was found that the test combination reduced the bacterial burden in the infected wounds by 91·3%. Pathological and histological analyses have revealed a decline in cell infiltration in the excisional wound skin tissue after treatment with rosuvastatin and levofloxacin combination. Conclusions Rosuvastatin combined with levofloxacin can be considered as a promising solution to combat S. aureus antibiotic resistance phenomenon. Significance and Impact of the Study This study unveils the potential effect of rosuvastatin when used in combination with levofloxacin can be used as a topical antibacterial agent to treat S. aureus skin infections.

show abstract

Dexamethasone abrogates the antimicrobial and antibiofilm activities of different drugs against clinical isolates of Staphylococcus aureus and Pseudomonas aeruginosa

Abstract: Graphical abstract

Cited by 17 publications

References 35 publications

Small Molecules Produced by Commensal Staphylococcus epidermidis Disrupt Formation of Biofilms by Staphylococcus aureus

Small Molecules Produced by Commensal Staphylococcus epidermidis Disrupt Formation of Biofilms by Staphylococcus aureus

Continuous Local Antibiotics Perfusion Therapy for Acute Deep Infections after Open Fractures

Potent synergistic combination of rosuvastatin and levofloxacin against Staphylococcus aureus : in vitro and in vivo study

Contact Info

Product

Resources

About